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Abstract 1 
Monoclonal antibodies (mAbs), which are now more frequently administered by subcutaneous (SC) 2 
injection rather than intravenously, have become a tremendously successful drug format across a 3 
wide range of therapeutic areas. Preclinical evaluations of mAbs to be administered by SC injection 4 
are typically performed in species such as mice, rats, minipigs, and cynomolgus monkeys to obtain 5 
critical information regarding formulation performance and prediction of PK/PD outcomes needed 6 
to select clinical doses for first-in-human studies. Despite extensive efforts, no preclinical model has 7 
been identified to date that accurately predicts clinical outcomes for these SC injections. We have 8 
addressed this deficiency with a novel in vitro instrument, termed Scissor, to model events occurring 9 
at the SC injection site and now further validated this approach using a set of eight mAbs for which 10 
clinical PK/PD outcomes have been obtained. Diffusion of these mAbs from the Scissor system 11 
injection cartridge into a large volume physiological buffer, used to emulate mAb movement from 12 
the SC injection site into the systemic circulation, provided distinct profiles when monitored over a 6 13 
h period. Curve-fitting analysis of these profiles using the Hill equation identified parameters that 14 
were used, along with physicochemical properties for each mAb, in a partial least squares analysis to 15 
define a relationship between molecule and formulation properties with clinical PK outcomes. The 16 
results demonstrate that parameters of protein charge at neutral pH and isoelectric point (pI) along 17 
with combined formulation properties such as viscosity and mAb concentration can dictate the 18 
movement of the mAb from the injection cartridge to infinite sink compartment. Examination of 19 
profile characteristics of this movement provided a strong predictive correlation for these eight 20 
mAbs. Together, this approach demonstrates the feasibility of this in vitro modelling strategy as a 21 
tool to identify drug and formulation properties that can define the performance of SC injected 22 
medicines and provide the potential for predicting clinical outcomes that could be useful for 23 
formulation selection and a first-in-human clinical dosing strategy.   24 
  25 
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Introduction 1 
The subcutaneous (SC) route is increasingly being used for the delivery of biopharmaceuticals such 2 
as therapeutic monoclonal antibodies (mAbs), as this route provides a more rapid, convenient, and 3 
cost-effective alternative to intravenous infusions. The most widely used preclinical species in the 4 
development and evaluation of monoclonal antibody mAb formulations are mice, rats and non-5 
human primates [1], with the more recent adoption of minipigs [2]. Although progress has been 6 
made relating preclinical models to human outcomes of pharmacokinetic (PK) parameters and 7 
pharmacodynamics (PD), especially in terms of clearance and volume of distribution [3], predicting 8 
human mAb absorption from the SC injection site using preclinical data remains a challenge [4]. For 9 
example, the percent bioavailability (%BA or F) of a recombinant human monoclonal anti-VEGF 10 
antibody administered SC has been reported as 100% in mice, 98% in cynomolgus monkeys and 69% 11 
in rats [5] and rituxumab %BA in rats varied between 18-44% based upon dose and SC injection 12 
location [6]. More troubling is the fact that %BA outcomes in man often do not correlate with 13 
preclinical data: adalimumab %BA in monkeys is 96%, but 64% in man; omalizumab %BA in mice is 14 
90%, 64-104% in monkeys, but 62% in man; golimumab %BA in monkeys is 77%, but 53% in man; 15 
and ustekinumab %BA in monkeys is 97%, but 24-95% in man [7, 8].  16 
The poor correlation between outcomes in pre-clinical species and humans in terms of mAb 17 
absorption following SC injection has been attributed not only to species-specific physiological and 18 
anatomical features of the SC tissue, but also to the relatively larger injection volumes frequently 19 
used in animal models when compared to overall body size [9]. To take into account species 20 
differences, allometric scaling has been used for predicting PK/PD of mAbs based on pre-clinical data 21 
[10]. This method has been reported as successful for predicting mAb clearance, but appears 22 
unsuitable for predicting mAb absorption rate and %BA following SC injection [11]. Physiologically-23 
based pharmacokinetic modelling (PBPK) has been used with moderate success to predict the 24 
maximum plasma concentration (Cmax) and time to reach the peak plasma concentration (tmax) of 25 
subcutaneously administered therapeutic proteins, including mAbs [12], but this method failed to 26 
predict %BA. Correlating binding affinity of a mAb to the neonatal IgG receptor FcRn has shown 27 
promise in predicting %BA as mAbs having a higher binding to the FcRn receptor showed higher %BA 28 
[13]. It has also been reported that formulation properties have an influence on the bioavailability of 29 
subcutaneously administered mAbs; for example, increasing the formulation osmolarity of rituximab 30 
in a rat model led to an increased %BA [14].  31 
Quality-by-design (QbD) is a paradigm that builds product and process parameters into a drug 32 
development program at the beginning to ensure therapeutic efficacy and safety of the active 33 
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pharmaceutical ingredient (API) and its formulation rather than relying entirely on testing of the end 1 
product. The QbD concept is based on the identification of critical quality attributes (CQAs) that 2 
define product attributes critical for the efficacy and safety of the final product [15]. For mAbs, CQAs 3 
include parameters related to physical properties of the molecule, such as size, charge, oxidation 4 
level, and Fc chain glycosylation [16]. There are also CQAs related to formulation composition, 5 
adventitious agents, and product specific attributes such as visible and sub-visible particulates and 6 
sterility for liquid formulations [16].  7 
For drugs delivered via the oral route, in vitro dissolution testing is used to identify CQA parameters 8 
that define a robust dosage formulation where a desired cumulative release drug profile can be 9 
consistently achieved [17]. For SC injected drugs, including protein therapeutics such as mAbs, 10 
however, have not had a method to assess CQA parameters related to absorption of a 11 
biopharmaceutical from an injected formulation. The lack of an assessment tool plays strongly into 12 
the rationale for variable and unpredictable clinical %BA outcomes for SC injected mAbs, as noted 13 
above. The SC injection site simulator (Scissor) mimics a number of the chemical, physical and 14 
physiological properties of the human SC injection site and enables monitoring events related to the 15 
stability of injected formulation components and their migration from the injection site [18]. In some 16 
ways, the Scissor system provides an in vitro method that parallels the examination of oral dosage 17 
form performance to define CQA parameters. Importantly, Scissor can provide a tool to examine 18 
injection site events as the environment in which the injected drug is exposed transitions from being 19 
in a drug product formulation to conditions consistent with the homeostatic state of the body. In the 20 
current study, we used the Scissor system to obtain data describing the movement of eight mAbs 21 
from the artificial injection site into the infinite sink reservoir of this instrument to model their 22 
absorption from the SC injection site into the systemic circulation.  23 
The Hill equation can be used to describe the binding of a ligand to a macromolecule, which can be 24 
modified by the previous binding of that ligand to other sites on the macromolecules or by the 25 
presence of other ligands [19, 20]. We considered the possibility that an individual mAb could be a 26 
ligand whose interactions with ECM components of the SC injection site could be affected by other 27 
agents in or properties of the formulation environment. Our studies now demonstrate that analysing 28 
Scissor-generated dissolution data using the Hill equation as well as the molecule and formulation 29 
properties for that specific mAb provided a strong correlation to human %BA outcomes for this set 30 
of mAbs. Thus, this approach may be useful for screening potential mAbs formulations in vitro early 31 
in development to possibly predict %BA outcomes in man and may be useful in the identification of 32 
formulation CQAs for this class of therapeutic agents.  33 
34 
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Experimental 1 
Materials 2 
Sodium chloride (NaCl), magnesium chloride hexahydrate (MgCl2•6H2O), potassium chloride (KCl), 3 
calcium chloride (CaCl2), sodium bicarbonate (NaHCO3), sodium phosphate (NaH2PO4) and sodium 4 
diphosphate (Na2HPO4) as well as sodium azide (NaN3), phosphate buffered saline (PBS) tablets and 5 
hyaluronic acid (HA) from Streptococcus equii were purchased from Sigma (Gillingham, UK). 6 
Monoclonal antibody (mAb) formulations were donated by Genentech, Inc. (South San Francisco, 7 
CA, United States). Information provided for each anonymized antibody is listed under “results” 8 
without details for the specific methods used to determine the listed values for each mAb.   9 
Scissor 10 
The subcutaneous injection site simulator “Scissor” was obtained from Sirius Analytical Ltd. (now 11 
PION, Forest Row, UK). Using a 1 ml disposable syringe (Thermo Fisher, Cramlington, UK) and a 16 12 
mm 25G needle (Becton Dickinson, Oxford, UK), 0.5 ml of each mAb formulation was injected into 13 
the Scissor cartridge (Sirius Analytical Ltd, UK, now PION) filled with 6.25 mg/ml hyaluronic acid (HA) 14 
in PBS solution that had been allowed to equilibrate at 34˚C in the surrounding “infinite sink” 15 
chamber conditions. The chamber was filled with physiological, carbonate based buffer solution, 1 16 
litre of which contains 6.4 g NaCl, 0.09 g MgCl2•6H2O, 0.4 g KCl, 0.2 g CaCl2 and 2.1 g NaHCO3 17 
dissolved in Milli-Q water, maintained at 34°C and pH 7.4 by bubbling CO2(g) through the solution. 18 
The buffer also contained 0.02% NaN3 to prevent bacterial growth during the experiments.  Aliquots 19 
of varying volumes, depending on assay limits of quantitation were taken from the buffer chamber 20 
at 2, 5, 10, 20, 30, 40, 50, 60, 90, 120, 180, 240, 300 and 360 min after injection. All mAb 21 
formulations were analysed in triplicate. 22 
Analysis of mAb movement from Scissor cartridge  23 
Aliquots taken from the infinite sink chamber were filtered with a low protein-binding 0.22 µm 24 
Millex GV disposable syringe filter (Merck Millipore, Feltham, UK) to remove particulates prior to 25 
analysis by high performance liquid chromatography using an Agilent 1260 Infinity HPLC system.  The 26 
injection volume was set to 100 µL, flow rate to 0.5 mL/min, oven temperature to 25˚C, and 27 
detection wavelength to 214 nm. A Yarra SEC-3000 size exclusion chromatography column (300 mm 28 
x 7.8 mm) with compatible pre-column filter (all from Phenomenex, Macclesfield, UK) was used for 29 
the separation. The mobile phase was 0.2 M potassium phosphate buffer (pH 6.2) with 0.25 M 30 
potassium chloride. Standard samples. prepared by diluting each mAb formulations to cover the 31 
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range of concentrations expected from samples captured from the infinite sink compartment, were 1 
used to determine the amount of injected mAb moving into the infinite sink compartment over time.  2 
Parametrisation of Scissor data 3 
KinetDS software was used to identify the mathematical model that best described Scissor profile 4 
data [21]. Based on this software screening, the Hill equation (Equation 1) was identified as the best 5 
model for fitting the data. SigmaPlot 12.5 (Systat Software Inc.) was used for plotting and final 6 
parametrisation of data using the Hill equation  7 
%𝑅𝑒𝑙𝑒𝑎𝑠𝑒𝑑 =
𝑎∗𝑥𝑏
𝑐𝑏+ 𝑥𝑏
     Equation 1 8 
where a represents the maximum fraction of protein moving from the injection cartridge to the 9 
infinite sink compartment, b is a shape factor for the curve, c is the time at which half of a has been 10 
achieved, and x is time. 11 
Partial least squares analysis 12 
Minitab 17 (Minitab Ltd, Coventry, UK) was used to analyse the dataset. First, principal component 13 
analysis (PCA) was conducted to identify possible correlations between system input variables to 14 
find out the number of components that adequately described relationships between input 15 
parameters of the dataset; PCA is a technique that enables analysis of relationships between a group 16 
of variables that may be collinear in nature, and which reduces the original input variables to a 17 
number of components that describe the underlying data in fewer dimensions [22]. The number of 18 
components that adequately described the input data was identified from the inflection point of the 19 
curve where it levelled off (“the elbow”) within the scree plot [23] while also ensuring that the 20 
model described more than 80% of the variation within the dataset [24]. Partial least squares (PLS) 21 
analysis, which is a form of PCA analysis that allows relating the input parameters to output 22 
parameters was then conducted to see how the different formulation and molecule properties as 23 
well as the Hill equation parameters related to outcomes for %BA and mean absorption rate 24 
constant (ka) in humans.  25 
Human in vivo data 26 
Human SC %BA and absorption rate values for the eight mAbs in this study were obtained from a 27 
population PK analysis of all available clinical data at the time of this manuscript’s preparation.  For a 28 
given antibody, the clinical serum PK data across all patients was pooled and simultaneously fit to its 29 
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population PK/PD model in order to estimate its PK parameters, including but not limited to %BA 1 
and absorption rate from the SC space.  2 
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Results 1 
Material attributes of mAb molecules tested and their formulations 2 
Commonly-assessed physicochemical properties of the mAbs examined in these studies and their 3 
formulations are summarised in Table 1. All mAbs have molecular weight (MW) values of ~145 kDa. 4 
Isoelectric point (pI) values for these mAbs varied between 6.1 and 9.1, resulting in theoretical 5 
charges between -5.3 and +16.2 at the physiological pH of 7.4. Protein concentration in the 6 
formulations  for these mAbs ranged from 100 to 180 mg/mL. Formulation buffer concentrations 7 
varied between 20 and 200 mmol/L, but formulation pH was within a narrow range of 5.5 to 6.0. 8 
Formulation viscosities ranged between 5 and 80 centipoise (cP). Additionally, the buffer species in 9 
all the formulations was histidine apart from mAbs 5 and T where arginine was used.  10 
Table 1. A summary of mAb attributes and formulation parameters. 11 
Molecule Formulation parameters 
mAb 
designation 
pIa 
Theoretical 
charge at pH 
7.4b 
Protein 
concentration 
(mg/mL) 
Buffer 
concentration 
(mmol/L) 
pH 
Viscosity 
(cP)c 
mAb 2 7.6 1.0 125 30 6.0 80 
mAb 3 8.5 4.9 100 30 5.5 3 
mAb 4 9.0 8.8 150 20 5.8 7 (RT) 
mAb 5 7.2 -3.3 150 200 5.5 10 (RT) 
mAb 6 9.4 16.2 180 20 6.0 9 (RT) 
mAb L 6.1 -5.3 125 20 5.7 7 
mAb T 9.1 13.0 150 200 5.5 5 
mAb F 8.7 9.0 150 30 5.5 12 
aDetermined by isoelectric focusing.  bCalculated based on pKa values of amino acids in the 12 
sequence. cMeasured at 25˚C except where otherwise denoted, RT = Room temperature. 13 
 14 
Profiles of mAb movement obtained using the Scissor system  15 
In vitro concentration-time profiles of mAbs in the infinite sink for the eight mAbs tested using the 16 
Scissor system were determined over a 6 h period (Fig. 1). Data points, obtained by HPLC analysis, 17 
represent an average from three repeats with the error bars displaying the standard deviation 18 
Kinnunen Bown et al 
 9 
between the experiments. Experimental work was carried out in a random order to ensure that 1 
differences observed reflected variations of the mAb formulation being examined rather than a 2 
systematic experimental error. In contrast to a previous publication using this type of in vitro model 3 
[18], the present studies included 0.02% (~ 3mM) sodium azide to limit bacterial growth during the 4 
6-hr time course used for infinite sink sampling. Importantly, four of the eight antibodies evaluated 5 
in this present study were also examined in the previous study in the absence of sodium azide with 6 
extremely similar outcomes in both cases. Of the mAbs investigated, mAb 5 left the injection 7 
cartridge the most rapidly, whereas the initial movement of mAb F was the slowest and the least 8 
overall after 6 h. Overall, mAb 2 showed the greatest extent of movement from the injection 9 
cartridge to the infinite sink compartment.  10 
Individual data sets and fitted curves allowed for a more refined assessment of profile variability for 11 
each mAb as it moved from the injection cartridge to the infinite sink compartment (Supplementary 12 
Figure 1). Concentration-time profiles showed greater variability for mAbs 2 and 3 compared to the 13 
other mAbs (Supplementary Figure 1). In the case of mAb 2, the greater variability between repeats 14 
may have been due to its higher formulation viscosity, making precise consistency between 15 
injections more challenging. Additionally, the pI of mAb 2 is close to physiological pH, where small 16 
changes in pH may influence interactions between this particular mAb and HA within the injection 17 
cartridge in a more dramatic fashion. Since the amount of mAb 3 detected in the infinite sink 18 
compartment at 300 and 360 min showed a decline compared to that observed at 240 min, data 19 
analysis was performed only up to the 240-min time point (Supplementary Fig. 1B). This decrease in 20 
mAb 3 concentration may be indicative of protein instability in the infinite sink buffer (and thus, 21 
possibly under physiological conditions as well) for longer periods of time. Indeed, some of the 22 
variability within results obtained for several of the mAb may have been due to protein instability. 23 
The inability to accurately measure mAb3 in the infinite sink after 240 min did not preclude the 24 
ability to define release characteristics for this antibody from the Scissor cartridge as there was 25 
ample data available from the earlier time points for curve fitting [25].  26 
 27 
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 1 
Figure 1. Data points obtained from the Scissor experiments at 6.25 mg/ml HA concentration for the 2 
different mAbs. Data represents average ± S.D, n=3.  3 
 4 
Parametrisation of Scissor data 5 
Comparison of curve-fitting outcomes using the Hill equation for concentration-time averages 6 
demonstrated distinct profiles for these eight mAbs (Fig. 2). These plots demonstrate clear 7 
differences in the initial rate as well as total extent of mAb movement from the Scissor cartridge to 8 
the infinite sink compartment. These differences are reflected within the Hill curve parameters a, b, 9 
and c; values of a range from 54.49 to 82.93 %, b from 1.32 to 1.75 and c from 35.60 to 116.80 10 
minutes (Table 2). The standard estimate of error (SEE) for each fitted curve was also calculated, 11 
with the low values obtained demonstrating that the Hill equation fits the Scissor data well (Table 2).   12 
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 1 
Figure 2. Hill curves fitted to averaged data points shown in Figure 1 for the different mAbs.  2 
 3 
Table 2. The Hill equation analysis derived from Scissor concentration-time profiles 4 
 a ± SD (%) b ± SD c ± SD (min) SEE 
mAb 2 82.93 ± 12.04 1.32 ± 0.26 105.90 ± 30.35 7.71 
mAb 3 54.49 ± 4.57 1.32 ± 0.23 35.87 ± 6.15 5.11 
mAb 4 67.79 ± 2.45 1.55 ± 0.15 55.44 ± 4.01 3.87 
mAb 5 64.94 ± 0.89 1.53 ± 0.07 35.60 ± 1.08 1.95 
mAb 6 62.08 ± 0.90 1.75 ± 0.07 64.98 ± 1.73 1.48 
mAb L 70.13 ± 2.31 1.47 ± 0.11 62.95 ± 4.20 3.01 
mAb T 60.32 ± 1.66 1.51 ± 0.10 62.74 ± 3.44 2.27 
mAb F 61.70 ± 2.52 1.62 ± 0.10 116.80 ± 8.14 1.88 
Hill equation parameters a, b and c for the different mAbs and standard error of estimate (SEE) for 5 
each of the fits are presented. Values represent mean ± standard deviation (SD) (n=3).  6 
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 1 
Using Scissor outcomes to predict human PK parameters  2 
Partial least squares (PLS) analysis was examined to develop a model to describe the relationship 3 
between a mAb and its formulation properties with regard to PK outcomes and identify formulation 4 
properties and physicochemical parameters of the mAbs that may potentially act as CQAs. In PLS 5 
analysis, a principal component analysis (PCA) is first conducted to determine the number of 6 
components that describe the variation within the dataset. PCA reduces the individual input 7 
parameters into latent parameters that describe the relationships that exist within the input 8 
parameters in fewer components [26]. We observed that, in addition to using the PCA results to 9 
identify the number of components to be used in the PLS-based prediction of %BA and ka values for 10 
these mAbs, the PCA analysis also furthered our understanding of Hill equation parameters; PCA for 11 
the dataset was conducted using molecule and formulation properties (Table 1) and Hill analysis 12 
parameters (Table 2) as input parameters.  13 
A loading plot for this PCA described relationships between different input parameters in terms of 14 
the two first components of the data set (Fig. 3). Adjacent parameters within the loading plot are 15 
frequently considered as closely related [22]. A loading plot for the first two components 16 
demonstrated that the Hill equation parameter a was related to formulation viscosity, parameter b 17 
was related to mAb charge and isoelectric point as well as the formulation concentration, and 18 
parameter c was related to formulation pH; formulation buffer concentration was independent from 19 
the other input variables (Figure 3).  20 
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1 
Figure 3. Loading plot of the two first components describing the relationships between input 2 
parameters for the set of monoclonal antibodies tested in the Scissor system.  3 
 4 
A scree plot, which shows the fraction of total variance in a data set, was used to identify the 5 
number of components used in subsequent PLS analysis [22]. The number of components that 6 
described the variation within this dataset of mAbs obtained from the Scissor system was 7 
established at 4 for the PCA analysis (Fig. 4); the components selected should explain at least 80% of 8 
the variation within the data. In this case, a transition was observed between 3 and 4 components, 9 
with 77% or 88% of the variation explained using 3 or 4 components, respectively (Table 3). The 10 
transition from 3 to 4 components correlated with an inflection in the scree plot (Fig. 4; arrow).  11 
 12 
 13 
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 1 
Figure 4. Scree plot of PCA analysis with respect to input parameter number. Curve inflection 2 
(elbow) is highlighted with an arrow.  3 
Table 3. Model selection for PLS analysis of human %BA and ka outcomes  4 
Number of 
components 
within the model 
X-Variance R2 for %BA R2 for ka 
1 0.33 0.16 0.76 
2 0.53 0.73 0.80 
3 0.78 0.85 0.81 
4 0.88 0.88 0.88 
Variance and correlation confidence for %BA and ka predicted values were derived using the PLS 5 
model and compared to human PK parameters.  6 
The importance of different input parameters considered in these studies within the model 7 
predicting %BA and ka can be assessed by considering the standard coefficients for each of the 8 
parameters independently in the context of these two PK outputs (Figure 5). In the case of predicting 9 
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%BA, formulation pH dominated the predictive outcomes, with values obtained for the Hill equation 1 
b parameter and formulation mAb concentration having diminished, but still positive, correlations 2 
(Fig. 5A). It should be noted that, individually, factors such as the Hill equation a parameter, 3 
formulation viscosity, formulation buffer concentration, pI, theoretical mAb charge at pH 7.4, and 4 
the Hill equation c parameter did not correlate with %BA outcomes. Formulation viscosity, both a 5 
and c parameters derived from the Hill equation fitting, as well as formulation buffer concentration 6 
demonstrated contributions towards the ka outcomes (Fig. 5B).  7 
This assessment of parameters individually correlating with %BA and ka outcomes must be 8 
considered in light of the loading plot analysis performed for these elements (Fig. 3). While 9 
formulation pH dominated the predictive outcomes for %BA, there was an opposite correlation with 10 
the c parameter derived from the Hill equation fitting. The b parameter derived from the Hill 11 
equation fitting and formulation mAb concentration also showed a positive correlation with %BA 12 
outcomes. Parameters correlating with ka outcomes were much more diverse compared to that 13 
observed for %BA outcomes. Here, elements from essentially all sectors of elements identified in the 14 
loading plot analysis were represented. From this summary of data, we hypothesize that human ka 15 
outcomes for this set of mAbs are responsive to a wide range of the parameters identified and 16 
evaluated here and that a more composite perspective where multiple parameters are considered is 17 
required to obtain a predictive understanding of outcomes obtained from the Scissor system data.  18 
 19 
A) 
 
B) 
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Figure 5. Standardised coefficients calculated for the different input parameters within the model to 1 
predict A) human %BA and B) human ka outcomes for the antibodies evaluated by the Scissor 2 
system. 3 
 4 
The previous analysis points to multiple parameters impinging upon the movement of these eight 5 
mAbs from the injection cartridge to the infinite sink compartment in the Scissor system. We tested 6 
this hypothesis by using the PLS model to obtain predicted values for %BA and ka. Comparison of 7 
these predicted outputs correlated favourably with data obtained experimentally in humans for 8 
these same eight mAbs (Fig. 6). In this format, R2 values were determined to be 0.87 and 0.88 for 9 
correlations of %BA and ka, respectively (Table 3).   10 
 11 
A) 
 
B) 
 
Figure 6. Linear correlation assessment for human in vivo data and PLS-based modelling of Scissor 12 
system data outputs for A) %BA based on 4 components (R2= 0.87) and for B) ka based on 4 13 
components (R2= 0.88).  14 
Comparison of %BA obtained from pre-clinical models, Scissor, and human 15 
In order to better assess the potential predictive value of data obtained from the Scissor instrument, 16 
we compared %BA outcomes for the eight mAbs used in these studies in the context of any available 17 
%BA outcomes in preferred pre-clinical models of minipig and cynomolgus monkey (Figure 7). Error 18 
bars have been omitted from the figure as different notations of error were used. Here, we could 19 
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make comparisons for data in minipig for four of these antibodies and in cynomolgus monkey for 1 
four antibodies. In the case of mAb T and mAb F, preclinical information on %BA for both minipig 2 
and cynomolgus monkey was available. For mAbs 2 and 4 there is preclinical data in monkey and for 3 
mAbs 6 and L preclinical data in minipig was available. No preclinical information for mAb 4 and mAb 4 
5 was available. The data demonstrates that the model developed in the current study for these 5 
eight mAbs provides a better estimate of human %BA outcome than either of the preclinical species. 6 
This comparison also supported previously stated observations that %BA outcomes in monkeys are 7 
often higher than that observed in man and that neither monkey or minipig outcomes are predictive 8 
for human clinical outcomes [2, 7, 8]. While these preclinical models tend to overestimate %BA 9 
outcomes compared to that observed in humans, analysis described herein based upon Scissor 10 
system data provides a reasonable prediction of human %BA for this set of eight mAbs.  11 
 12 
Figure 7. %BA outcomes for the different mAbs in human, monkey and minipig as well as the %BA 13 
predicted using the model developed during the current study. The data for Scissor represents the 14 
value as predicted with the PLS model. The minipig data is adapted from [2]. For cynomolgus 15 
monkey the median value of reported ranges has been plotted. For human, minipig and cynomolgus 16 
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monkey the %BA has been plotted. Error bars have been omitted due to inconsistencies in how 1 
variability was  reported (SEE vs. RSE vs. %CV) for these values. 2 
 3 
  4 
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Discussion 1 
Accurate prediction of PK/PD outcomes is critical for selecting clinical doses for first-in-human 2 
studies. Despite the value of such information, there is currently no validated in vivo preclinical or in 3 
vitro model to provide this data in the case of biopharmaceuticals, including mAbs. Clinical outcomes 4 
for measured %BA of SC injected mAbs are frequently much lower than 100% and often in the range 5 
of 40-60% [27], despite pre-clinical model outcomes often demonstrating much higher %BA 6 
outcomes [28]. While clearance mechanism differences between humans and these non-human 7 
models may account for some of these discrepancies [29], a systematic examination of potential 8 
differences in the minipig model has failed to identify critical factors that might provide a predictive 9 
model [2]. While still highly valuable to assess a plethora of safety and toxicological concerns, the 10 
anatomical and physiological differences of the SC space for these various pre-clinical animal models 11 
and humans may provide an explanation for this lack of predictability for %BA and ka outcomes [30]. 12 
The recently-developed Scissor system potentially represents a model that may be useful to 13 
investigate events associated with the SC administration of a biopharmaceutical as it was established 14 
using parameters intended to emulate dynamic events occurring at the SC injection site that might 15 
occur after introduction of a non-physiological formulation [18]. Four mAbs were previously 16 
examined in a prototype version of the Scissor system, with a clear correlation of mAb movement 17 
from the artificial injection site being established with clinical %BA outcomes being identified [18]. 18 
We now extend those studies with the addition of four additional human mAbs to a make a total set 19 
of eight human mAbs where clinical %BA outcomes were available using commercially-available 20 
Scissor system.  21 
The absolute concentration of HA in the human SC site is unknown [30]. In the prototype Scissor 22 
system, 10% HA content was used to establish a SC injection site environment that correlated with 23 
clinical %BA outcomes for the first four mAbs examined [18]. In the commercial Scissor system used 24 
in the current study, we found that 6.25% HA was sufficient for correlation with clinical %BA 25 
outcomes for the set of eight mAbs examined. This alteration in HA concentration accounted for a 26 
change in the injection site cartridge configuration from a dialysis cassette to a cuvette where the 27 
volume and path length for release into the infinite sink were different: in the prototype system, the 28 
cartridge volume was 3 mL and in the commercial version cartridge volume is now 5 mL. Thus, the 29 
total amount of HA within the cartridge remained constant between the two systems (Suppl. Figure 30 
3). The thin dialysis cassette used in the prototype system limited examination of differences of 31 
initial rates and profile of mAb movement from the simulated injection site to the infinite sink 32 
compartment; the current injection cartridge configuration provides greater diffusional distances 33 
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prior to detection within the external buffer, emulating the infinite sink of systemic circulation in the 1 
case of the cassette versus the cartridge. Thus, the commercial Scissor system appears to provide a 2 
better design to compared to the prototype format for examining diffusional properties of injected 3 
formulation components.    4 
While the goal of the Scissor instrument is to mimic certain physical, chemical and physiological 5 
properties of SC tissue, we cannot definitively state that all of the essential elements of the SC 6 
injection site that define the fate of these mAbs in patients have been incorporated. What we can 7 
say is that the criteria used to evaluate the fate of this set of eight mAbs in the current system was 8 
sufficient to demonstrate different diffusional behaviours that correlated well with %BA and ka 9 
outcomes in man. Using the commercial Scissor system, we could identify a number of formulation 10 
component parameters that appeared to control the movement of these eight mAbs from the 11 
injection cassette into the infinite sink buffer reservoir. While all eight of the mAbs examined in 12 
these studies had very similar molecular weights, they had distinct surface charge properties and 13 
their formulations varied in the buffer used, pH, viscosity, and ionic strength. Thus, it is not 14 
surprising that we identified a combination of factors that correlated with the movement of these 15 
mAbs from the injection site cartridge into the infinite sink compartment and that could be 16 
envisioned to affect their fate following their SC injection in patients. It is unclear if additional 17 
parameters beyond those identified in the present studies, such as other physicochemical properties 18 
of the mAbs or aspects of the formulations, could be used to further refine the predictive outcomes 19 
demonstrated presently. The information acquired through the present parameterization, however, 20 
appears to be potentially useful for a QbD approach for formulation design and optimisation.  21 
Parametrisation of data obtained from the Scissor system was initiated by curve fitting with the Hill 22 
equation to describe binding interactions similar to those observed in a variety of biochemical and 23 
pharmacological processes [31, 32]. The Hill equation parameter a describes the maximum amount 24 
of drug fraction moving from the Scissor cartridge to the infinite sink compartment. Using PCA, we 25 
could show this parameter was affected by formulation viscosity, further supporting the benefit of 26 
the commercial cartridge dimensions compared to the prototype dialysis cassette format as a 27 
refinement of the system that improved the ability of the Scissor system to characterize diffusional 28 
properties of injected materials. We failed to observe a direct correlation between a and %BA for 29 
this series of mAbs in humans (data not shown, R2= 0.0173). Thus, additional physical properties of 30 
the mAb and formulation components must affect the fate of these mAbs following SC injection, 31 
possibly through processes that involve both specific and/or non-specific electrostatic interactions 32 
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between positively-charged domains of the mAb and the most common negatively-charged material 1 
present in the SC space, HA [33]. 2 
As b is a coefficient of the Hill equation that should describe the drug movement from the Scissor 3 
cartridge to the infinite sink compartment, we hypothesised that this parameter may help describe 4 
initial interactions between the mAb and injection compartment components that could involve 5 
initial solubility and/or binding events. PCA loading plot analysis demonstrated a close relationship 6 
between the pI of the mAb, its charge at physiological pH, concentration of mAb in the formulation 7 
and the value of b. This correlation is interesting as historically the value of b obtained from the Hill 8 
equation was considered as an indicator of binding reaction stoichiometry; the value is now more 9 
widely accepted as an indicator of the mass balance of binding events [34]. Therefore, non-specific 10 
electrostatic interactions between HA and any positively charged molecules within the Scissor 11 
injection site cartridge can potentially influence the rate and extent of drug movement from the 12 
injection cuvette. Thus, profiles of mAb release from the injection site compartment for the 13 
formulations tested in the current studies should have been sensitive to both the charge magnitude 14 
and mAb concentration available for these interactions. 15 
We also hypothesised that parameter c, which describes the time at which half of a has been 16 
achieved, may be related to ka outcomes in humans as both parameters describe time dependence 17 
of the drug absorption process. Interestingly, no direct correlation between ka and parameter c was 18 
observed (data not shown, R2 = 0.3888). Based upon the PCA loading plot that demonstrates a 19 
relationship between c and formulation pH, the value of c appears to reflect how interactions 20 
between a mAb and SC tissue components might be altered as the environment of the injection site 21 
transitions from that of the formulation environment to conditions that better reflect the 22 
homeostatic state of the body [18]. Given that no direct correlation between any of the Hill 23 
parameters and human PK properties could be identified, a PLS analysis of the dataset with the aim 24 
of predicting %BA and ka based on mAb molecule and formulation properties as well as the Hill 25 
parameters was conducted. Importantly, PLS analysis is best suited for analysing data where the 26 
input parameters outnumber the observations and where the data is collinear [35].  27 
Using the approach of PLS analysis that included Hill coefficients, protein physicochemical 28 
properties, and formulation characteristics for these mAbs, models for both %BA and ka were 29 
simultaneously developed, i.e. the same model was used for predicting both %BA and ka, not 30 
separate models. Here, correlations for a set of parameters to predict both %BA and ka were 31 
achieved with R2 values of 0.8718 and 0.8844, respectively. These outcomes support the importance 32 
of the input parameters used within a model; the larger the magnitude of the standardised 33 
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coefficient, the more important the parameter within the model. Using this approach, the Hill 1 
equation parameter c was identified as the most important parameter within the model for %BA 2 
with a coefficient of approximately -0.8. Formulation pH was the next most critical with a coefficient 3 
of approximately +0.5. Together, this suggests electrostatic interactions taking place between 4 
formulation components and the mAb may play a dominant role in determining %BA. For predicting 5 
ka, multiple parameters, including formulation viscosity, all the Hill parameters and buffer 6 
concentration have similar standardised coefficients of approximately +0.3 to +0.4. These findings 7 
indicate that the rate at which these mAbs are absorbed from the SC injection site is influenced by 8 
multiple factors.  9 
Finally, it is also noteworthy that when the PLS prediction of the human PK properties for this set of 10 
mAbs was performed with either only the Hill parameters or only the molecule and formulation 11 
properties, poor correlations were obtained (Supplementary Figures 2 and 3).  Therefore, our data 12 
indicates that the knowledge of both the molecule and formulation properties as well as the 13 
diffusional properties of the mAbs in the Scissor model are required for meaningful predictions of 14 
human PK properties.     15 
Conclusions 16 
Previous studies with the prototype Scissor system identified a trend toward correlation with human 17 
%BA outcomes. We have now used the commercial system to refine parameters associated with the 18 
mAb and its formulation to better understand this correlation. The Hill equation was successfully 19 
used for parameterising these Scissor profiles, with parameters a, b, and c being attributable to 20 
molecule and formulation properties: parameter a being related to formulation viscosity, parameter 21 
b being related to pI, physiological mAb charge at neutral pH, and formulation concentration, while 22 
parameter c related to formulation pH. A PLS model was developed using molecule properties, 23 
formulation properties, and the three Hill parameters that provided strong predictive power for 24 
human %BA and ka outcomes. This approach, and the resultant model, provides a novel tool for the 25 
antibody engineer or formulation scientist to assess how an individual factor (e.g., molecule charge 26 
at neutral pH, formulation pH, etc.) might directly impact PK outcomes of the molecule. The 27 
unavoidable shortcoming of this conclusion is the inability to validate specific hypotheses. For 28 
example, what happens when formulation pH is tuned by 0.5 units?  As human PK data is required to 29 
adequately assess the outcome, this can be prohibitively expensive. Continued use of the Scissor 30 
system and this approach with additional mAbs will likely provide an opportunity for further model 31 
validation and/or refinement and possibly for direct testing of such hypotheses. 32 
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Supplementary Figure 1. Hill curves fitted into the data points from Scissor 
experiments for mAb A) mAb 2, B) mAb 3, C) mAb 4, D) mAb 5, E) mAb 6, F) mAb 
F, G) mAb L, and H) mAb T (average ± S.D., n=3). 
 1 
  
Supplementary Figure 2. PLS prediction of %BA and ka with molecule and formulation properties.  
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Supplementary Figure 3. PLS prediction of %BA and ka with a, b and c. 
 1 
A) 
 
B) 
 
Supplementary Figure 4. Comparison of injection site compartments used in Scissor. A) Organization 
of the dialysis cassette used in the prototype system. A 3 mL Slide-A-Lyzer dialysis cassette, 0.60 x 
6.3 × 2.5 cm, was modifications as highlighted by the schematic. B) A 4.5 mL cuvette, 1 x 1 x 5 cm, 
cartridge used in the commercial system.  
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